1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

T Takahashi,K Mori,R Mizuno,N Mamesaya,H Kobayashi,S Omori,K Wakuda,A Ono,T Naito,H Murakami,H Kenmotsu

doi:10.1016/j.annonc.2021.08.235

1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

T Takahashi, K Mori + Show 9 more

Open Access

PDF Available

https://doi.org/10.1016/j.annonc.2021.08.235

Copy DOI

Export

Save

Cite

Journal: Annals of Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

#Extensive-stage Small Cell Lung Cancer #Recommended Dose #Study Of Ramucirumab #Ramucirumab In Combination #Cisplatin In Patients #Ramucirumab #anti-VEGF Antibody #Efficacy Of Agents #Prospective Phase #Single Phase

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

Some previous studies evaluated the efficacy of anitiangiogenic agents in ES-SCLC pts. This prospective single institutional phase I study aimed to determine the recommended dose (RD) of ramucirumab (RAM), anti-VEGF receptor-2 antibody, in combination with irinotecan (Iri) and cisplatin (Cis), and to perform an exploratory analysis of the efficacy and tolerability at RD in pts with ES-SCLC.

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)